FDA rejects ITM's radiopharma drug over manufacturing problems
The FDA rejected ITM Isotope Technologies Munich’s radiopharmaceutical agent for neuroendocrine tumors because of manufacturing issues, delaying a potential challenger to Novartis’ approved drug Lutathera. ITM said the agency cited manufacturing ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.